CPEX tells shareholders to delay action over Arcadia bid
This article was originally published in Scrip
Executive Summary
CPEX Pharmaceuticals is urging its shareholders to "take no action at this time" in response to an unsolicited bid for the US speciality pharma firm by Arcadia Capital Advisors' managing director Richard Rofe, who last week offered $16 per share in a tender offer.